Search Results for: RPS6KA1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
LNX1 ligand of numb-protein X 1
  • Antigen processing: Ubiquitination & Proteasome degradation
MAGI1 membrane associated guanylate kinase, WW and PDZ domain containing 1
MAGI2 membrane associated guanylate kinase, WW and PDZ domain containing 2
  • Nephrin family interactions
MAGI3 membrane associated guanylate kinase, WW and PDZ domain containing 3
MAPK1 mitogen-activated protein kinase 1
  • phospho-PLA2 pathway
  • RAF-independent MAPK1/3 activation
  • MAPK1 (ERK2) activation
  • Spry regulation of FGF signaling
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Frs2-mediated activation
  • ERK/MAPK targets
  • ERK/MAPK targets
  • ERKs are inactivated
  • Regulation of actin dynamics for phagocytic cup formation
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Oncogene Induced Senescence
  • FCERI mediated MAPK activation
  • Regulation of HSF1-mediated heat shock response
  • NCAM signaling for neurite out-growth
  • Recycling pathway of L1
  • RSK activation
  • Signal transduction by L1
  • Activation of the AP-1 family of transcription factors
  • Thrombin signalling through proteinase activated receptors (PARs)
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate NADPH Oxidases
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Neutrophil degranulation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signal attenuation
  • Advanced glycosylation endproduct receptor signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • ESR-mediated signaling
  • RUNX2 regulates osteoblast differentiation
  • Regulation of PTEN gene transcription
  • Regulation of the apoptosome activity
  • Estrogen-stimulated signaling through PRKCZ
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Suppression of apoptosis
  • Signaling downstream of RAS mutants
  • Signaling by MAP2K mutants
  • Signaling by MAPK mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated phagocytosis
  • Growth hormone receptor signaling
  • Acetylsalicylic acid
  • Minocycline
  • Isoprenaline
  • Arsenic trioxide
  • Olomoucine
  • Phosphonothreonine
  • Purvalanol
  • SB220025
  • Seliciclib
  • Perifosine
  • N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
  • (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
  • 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
  • (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
  • Turpentine
  • Ulixertinib
MAPK3 mitogen-activated protein kinase 3
  • MAPK3 (ERK1) activation
  • RAF-independent MAPK1/3 activation
  • ISG15 antiviral mechanism
  • Spry regulation of FGF signaling
  • Frs2-mediated activation
  • ERK/MAPK targets
  • ERK/MAPK targets
  • ERKs are inactivated
  • Regulation of actin dynamics for phagocytic cup formation
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Oncogene Induced Senescence
  • FCERI mediated MAPK activation
  • Regulation of HSF1-mediated heat shock response
  • NCAM signaling for neurite out-growth
  • RSK activation
  • Signal transduction by L1
  • Activation of the AP-1 family of transcription factors
  • Thrombin signalling through proteinase activated receptors (PARs)
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate NADPH Oxidases
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RNA Polymerase I Promoter Opening
  • Signal attenuation
  • Advanced glycosylation endproduct receptor signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • ESR-mediated signaling
  • RUNX2 regulates osteoblast differentiation
  • Regulation of PTEN gene transcription
  • Regulation of the apoptosome activity
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Suppression of apoptosis
  • Signaling downstream of RAS mutants
  • Signaling by MAP2K mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated phagocytosis
  • Growth hormone receptor signaling
  • Sulindac
  • Acetylsalicylic acid
  • Minocycline
  • Arsenic trioxide
  • Purvalanol
  • 5-iodotubercidin
  • Seliciclib
  • Cholecystokinin
  • Ulixertinib
MAPT microtubule associated protein tau
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Lansoprazole
  • Astemizole
  • Paclitaxel
  • Docetaxel
  • Flortaucipir F-18
  • Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
  • Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
  • Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
MAST1 microtubule associated serine/threonine kinase 1
  • Fostamatinib
MAST2 microtubule associated serine/threonine kinase 2
METTL1 methyltransferase like 1
  • tRNA modification in the nucleus and cytosol
MITF melanocyte inducing transcription factor
  • SUMOylation of transcription factors
  • Ocular albinism; Ocular albinism, type I (OA1); Waardenburg syndrome, type II (WS2-OA)
  • Waardenburg syndrome (WS)
  • Malignant melanoma
MPP1 membrane palmitoylated protein 1
MTOR mechanistic target of rapamycin kinase
  • PIP3 activates AKT signaling
  • Macroautophagy
  • MTOR signalling
  • mTORC1-mediated signalling
  • HSF1-dependent transactivation
  • Energy dependent regulation of mTOR by LKB1-AMPK
  • CD28 dependent PI3K/Akt signaling
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Regulation of TP53 Degradation
  • Regulation of PTEN gene transcription
  • Amino acids regulate mTORC1
  • Pimecrolimus
  • Sirolimus
  • Everolimus
  • Rimiducid
  • SF1126
  • XL765
  • Ridaforolimus
  • Temsirolimus
  • Fostamatinib
MXD1 MAX dimerization protein 1
NFKBIA NFKB inhibitor alpha
  • Activation of NF-kappaB in B cells
  • RIP-mediated NFkB activation via ZBP1
  • Downstream TCR signaling
  • NF-kB is activated and signals survival
  • FCERI mediated NF-kB activation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • SUMOylation of immune response proteins
  • IkBA variant leads to EDA-ID
  • CLEC7A (Dectin-1) signaling
  • Ub-specific processing proteases
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • Acetylsalicylic acid
  • Bardoxolone methyl
  • Astaxanthin
  • Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
  • Hodgkin lymphoma
NR4A1 nuclear receptor subfamily 4 group A member 1
  • AKT phosphorylates targets in the nucleus
  • Nuclear Receptor transcription pathway
  • Constitutive Signaling by AKT1 E17K in Cancer
NR4A2 nuclear receptor subfamily 4 group A member 2
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Parkinson's disease (PD)
NR4A3 nuclear receptor subfamily 4 group A member 3
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • Dasatinib
  • Extraskeletal myxoid chondrosarcoma
PARD3B par-3 family cell polarity regulator beta
PDCD4 programmed cell death 4
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation

Page 3 out of 5 pages